The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial
Abstract
BACKGROUND: Patients with type 2 diabetes who do not achieve glycemic control with oral agent therapy eventually require insulin. OBJECTIVE: To determine the effect on glycemic control of inhaled insulin alone or added to dual oral therapy (insulin secretagogue and sensitizer) after failure of dual oral therapy. DESIGN: Open-label, randomized, controlled trial. SETTING: 48 outpatient centers in the United States and Canada. PATIENTS: 309 patients with type 2 diabetes, no clinically significant respiratory disease, and hemoglobin A(1c) level of 8% to 11% who were receiving dual oral therapy. MEASUREMENTS: Primary end point was change in hemoglobin A(1c) level from baseline to 12 weeks. Secondary outcomes included hemoglobin A(1c) level less than 8% and less than 7%, hypoglycemia, weight, lipid levels, pulmonary function, insulin antibody binding, and adverse events. INTERVENTION: Inhaled insulin (Exubera; Pfizer Inc. [New York, New York], sanofi-aventis Group [Paris, France], and Nektar Therapeutics [San Carlos, California]), titrated to blood glucose, administered alone (n = 104) or added to dual oral agents (n = 103) versus oral therapy alone (n = 99). RESULTS: Reductions in hemoglobin A(1c) level were greater with inhaled insulin. Adjusted treatment group differences for inhaled insulin plus oral agents and inhaled insulin alone compared with continued oral agent therapy were -1.67 percentage points (95% CI, -1.90 to -1.44 percentage points; P < 0.001) and -1.18 percentage points (CI, -1.41 to -0.95 percentage point; P < 0.001), respectively. Hemoglobin A(1c) level less than 7% was achieved by 32% (inhaled insulin plus oral agents) and by 1% (oral agent therapy) of patients (adjusted odds ratio, 44.7 [CI, 6.0 to 335.2]). Hypoglycemia, mild weight gain, mild cough, and insulin antibodies were more frequent with inhaled insulin than with oral agent therapy alone. Pulmonary function was similar in all groups. LIMITATIONS: This study evaluated only patients with hemoglobin A1c levels of 8% to 11%, did not compare inhaled insulin with other insulins or oral therapy except a dual regimen of secretagogue and sensitizer, and lasted only 12 weeks. CONCLUSIONS: Inhaled insulin improved overall glycemic control and hemoglobin A1c level when added to or substituted for dual oral agent therapy with an insulin secretagogue and sensitizer. Consistent with other insulin therapies, hypoglycemia and mild weight gain occurred. Pulmonary function showed no between-group differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Asthenia 21 (20) 24 (23) 4 (4) Headache 6 (6) 7 (7) 0 (0) Hypoglycemia 78 (76) 69 (66) 8 (8) Total events 477 365 13 Severe events 0 1 0 Dizziness 11 (11) 24 (23) 3 (3) Nervousness 3 (3) 6 (6) 0 (0) Tremor 36 (35) 33 (32) 5 (5) Increased cough 7 (7) 5 (5) 0 (0)”
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202 · cited 2×
“mg/dL 192 (37) 1 (2) 193 (39) 1 (2) 187 (40) 4 (2) 5 ( 12 to 1) 3 ( 10 to 3)”
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873 · cited 2×
“Asthenia 21 (20) 24 (23) 4 (4) Headache 6 (6) 7 (7) 0 (0) Hypoglycemia 78 (76) 69 (66) 8 (8) Total events 477 365 13 Severe events 0 1 0 Dizziness 11 (11) 24 (23) 3 (3) Nervousness 3 (3) 6 (6) 0 (0) Tremor 36 (35) 33 (32) 5 (5) Increased cough 7 (7) 5 (5) 0 (0)”
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
Cited by
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Self-citationCurrent challenges in non-invasive insulin delivery systems: A comparative review
Khafagy, E.-S., Morishita, M., Onuki, Y., & Takayama, K. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.019 · Cited by 436
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420
Self-citation
Metadata
- Authors
- Rosenstock, J., Zinman, B., Murphy, L. J., Clement, S. C., Moore, P., Bowering, C. K., Hendler, R., Lan, S.-P., & Cefalu, W. T.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2005-10-18
- Volume
- 143
- Issue
- 8
- Pages
- 549-558
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1987028155
- Cited by
- 158
- References
- 7
- FWCI
- 22.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-143-8-200510180-00005
- The paper
- Rosenstock, J., Zinman, B., Murphy, L. J., Clement, S. C., Moore, P., Bowering, C. K., Hendler, R., Lan, S.-P., & Cefalu, W. T. (2005). Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-143-8-200510180-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.